Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Bortezomib in Treating Patients With Metastatic Kidney Cancer
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00276614
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Study of Velcade and Thalidomide in Patients With Myelodysplasia
- Conditions
- Myelodysplastic Syndrome
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2008-03-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT00271804
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 46
- Registration Number
- NCT00265928
- Locations
- 🇺🇸
University of Virginia Cancer Center at UV Health System, Charlottesville, Virginia, United States
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 18
- Registration Number
- NCT00262860
- Locations
- 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
Bortezomib in Treating Patients With Myelodysplastic Syndromes
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 8
- Registration Number
- NCT00262873
- Locations
- 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Lymphoma, Mantle-Cell
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2006-10-18
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 16
- Registration Number
- NCT00261612
- Locations
- 🇦🇹
Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology, Vienna, Austria
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Dietary Supplement: ascorbic acidDrug: arsenic trioxideDrug: bortezomibDrug: dexamethasoneDrug: thalidomideDrug: Aspirin
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT00258245
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
- Conditions
- Multiple Myeloma
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00257114
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT00250926
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
- Interventions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00243035
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.